Show simple item record

dc.contributor.authorIcso, Janneke
dc.contributor.authorThompson, Paul R
dc.date.accessioned2022-12-07T20:38:09Z
dc.date.available2022-12-07T20:38:09Z
dc.date.issued2022-07-01
dc.identifier.citationIcso JD, Thompson PR. The chemical biology of NAD+ regulation in axon degeneration. Curr Opin Chem Biol. 2022 Aug;69:102176. doi: 10.1016/j.cbpa.2022.102176. Epub 2022 Jul 1. PMID: 35780654.en_US
dc.identifier.eissn1879-0402
dc.identifier.doi10.1016/j.cbpa.2022.102176en_US
dc.identifier.pmid35780654
dc.identifier.urihttp://hdl.handle.net/20.500.14038/51410
dc.description.abstractDuring axon degeneration, NAD+ levels are largely controlled by two enzymes: nicotinamide mononucleotide adenylyltransferase 2 (NMNAT2) and sterile alpha and toll interleukin motif containing protein 1 (SARM1). NMNAT2, which catalyzes the formation of NAD+ from NMN and ATP, is actively degraded leading to decreased NAD+ levels. SARM1 activity further decreases the concentration of NAD+ by catalyzing its hydrolysis to form nicotinamide and a mixture of ADPR and cADPR. Notably, SARM1 knockout mice show decreased neurodegeneration in animal models of axon degeneration, highlighting the therapeutic potential of targeting this novel NAD+ hydrolase. This review discusses recent advances in the SARM1 field, including SARM1 structure, regulation, and catalysis as well as the identification of the first SARM1 inhibitors.en_US
dc.language.isoenen_US
dc.relation.ispartofCurrent Opinion in Chemical Biologyen_US
dc.relation.urlhttps://doi.org/10.1016/j.cbpa.2022.102176en_US
dc.rightsCopyright © 2022 Elsevier Ltd. All rights reserved.en_US
dc.subjectAxon degenerationen_US
dc.subjectHydrolaseen_US
dc.subjectNAD(+)en_US
dc.subjectNeuropathyen_US
dc.subjectSARM1en_US
dc.subjectWallerian degenerationen_US
dc.titleThe chemical biology of NAD regulation in axon degenerationen_US
dc.typeJournal Articleen_US
dc.source.journaltitleCurrent opinion in chemical biology
dc.source.volume69
dc.source.beginpage102176
dc.source.endpage
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryEngland
dc.identifier.journalCurrent opinion in chemical biology
atmire.contributor.authoremailjanneke.doedee@umassmed.eduen_US
atmire.contributor.authoremailPaul.thompson@umassmed.eduen_US
dc.contributor.departmentThompson Lab
dc.contributor.departmentBiochemistry and Molecular Biotechnologyen_US
dc.contributor.departmentMorningside Graduate School of Biomedical Sciencesen_US


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record